Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-09-05.

To ask Her Majesty’s Government how many patients were treated for hepatitis C and what were the actual or estimated costs of such treatment in each of the years 2014–15, 2015–16, and 2016–17.

Lord Prior of Brampton

Comprehensive data on all hepatitis C treatment in the United Kingdom is presented in the Public Health England annual report on Hepatitis C in the UK. The latest version published in July 2016 is called Hepatitis C in the UK 2016 report: Working towards its elimination as a major public health threat, and reported that treatment rates increased by around 40% in the calendar year 2015, up to 8,970 from an average of 6,400 in previous years. A copy of the report is attached. The report also presented preliminary figures to show that deaths in the UK from hepatitis C-related end stage liver disease and liver cancer fell for the first time in 2015, suggesting that access to new oral treatment via the early access schemes for patients with decompensated cirrhosis and cirrhosis may be having a positive impact.

In April 2014, NHS England announced an interim commissioning policy to make these new highly effective oral treatments available to patients with liver failure. In June 2014, NHS England implemented a second Interim Commissioning Policy, extending access to patients with cirrhosis.

Hepatitis C drugs are subject to commercially confidential discounts and rebate agreements. Releasing estimated or actual spend data includes the impact of these confidential prices which if released would inhibit the ability of companies to do business with the Department in the future. The Department has a duty to ensure that they adhere to the terms of confidentiality agreements when considering the release of information under the Pharmaceutical Price Regulation Scheme or other Commercial Medicines Unit drug framework agreements.